$ISIS Up to date company activities and other important

New Post Public Reply Private Reply Replies (0) Message Board

Mar 7, 2014 at 10:30 AM

$ISIS Up to date company activities and other important information about $ISIS

$ISIS

DD Notes ~ http://www.ddnotesmaker.com/ISIS

##### recent news/filings ~ source: finance.yahoo.com

Thu, 06 Mar 2014 23:07:34 GMT ~ Nasdaq stocks posting largest percentage increases
- A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: InterCloud Systems rose 22.9 percent to $12.90. Bind Therapeutics rose 12.0 percent to $15.40. RiceBran Tech rose 10.6 percent ...
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************

Thu, 06 Mar 2014 14:39:51 GMT ~ Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
- CARLSBAD, Calif., March 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays ...
read full: http://www.noodls.com/view/E271A050008217C258...FA17CBCAF3
*********************************************************

Thu, 06 Mar 2014 12:00:00 GMT ~ Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
- CARLSBAD, Calif., March 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, FL. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com. A replay will be available on the Isis website within 48 hours and will be archived for a limited time. Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH. Isis' patents provide strong and extensive protection for its drugs and technology. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
read full: http://finance.yahoo.com/news/isis-pharmaceut...00534.html
*********************************************************

Wed, 05 Mar 2014 19:32:08 GMT ~ Why Isis Pharmaceuticals Continues to Impress
read full: http://www.fool.com/investing/general/2014/03...lnk0000001
*********************************************************

Wed, 05 Mar 2014 16:50:00 GMT ~ Arrowhead Research: 'Early Innings' for 'Major Story'
read full: http://blogs.barrons.com/stockstowatchtoday/2...p;ru=yahoo
*********************************************************

##### chart ~ source: stockcharts.com

stockcharts.com/c-sc/sc?s=ISIS&p=D&b=5&g=0&id=p95448242713

##### chart ~ source: eoddata.com

http://chart.eoddata.com/?e=OTCBB&s=ISIS&...D&b=BB

##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/ISIS/filings
Latest financials: http://www.otcmarkets.com/stock/ISIS/financials
Latest news: http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines

Major holdings: http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ISIS

RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search

DTCC: http://search2.dtcc.com/?q=Isis+Pharmaceutica...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.isip.com
Alexa: http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.isip.com

Short Sales: http://www.otcmarkets.com/stock/ISIS/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ISIS/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ISIS/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ISIS+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ISIS+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet: http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow: http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ISIS
Bloomberg: http://www.bloomberg.com/quote/ISIS:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek: http://investing.businessweek.com/research/st...icker=ISIS
Barchart: http://www.barchart.com/quotes/stocks/ISIS
OTC Short Report: http://otcshortreport.com/index.php?index=ISIS
Investopedia: http://www.investopedia.com/markets/stocks/ISIS/?wa=0

http://www.pennystocktweets.com/stocks/profile/ISIS

##### last known share structure ~ source: otcmarkets.com

Market Value: $6,497,943,167 a/o Mar 06, 2014
Shares Outstanding: 117,270,225 a/o Feb 21, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

##### business description ~ source: otcmarkets.com

IC

DD Notes ~ http://www.ddnotesmaker.com/ISIS

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...